GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » Revenue

CRISPR Therapeutics AG (MEX:CRSP) Revenue : MXN3,395 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG Revenue?

CRISPR Therapeutics AG's revenue for the three months ended in Sep. 2024 was MXN0 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was MXN3,395 Mil. CRISPR Therapeutics AG's Revenue per Share for the three months ended in Sep. 2024 was MXN0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was MXN42.60.

During the past 12 months, the average Revenue per Share Growth Rate of CRISPR Therapeutics AG was 16.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 735.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 27.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 10 years, CRISPR Therapeutics AG's highest 3-Year average Revenue per Share Growth Rate was 735.70% per year. The lowest was -89.40% per year. And the median was 115.25% per year.


CRISPR Therapeutics AG Revenue Historical Data

The historical data trend for CRISPR Therapeutics AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Revenue Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,461.67 10.80 18,730.94 8.50 6,280.47

CRISPR Therapeutics AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3,394.85 - - -

Competitive Comparison of CRISPR Therapeutics AG's Revenue

For the Biotechnology subindustry, CRISPR Therapeutics AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Revenue distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Revenue falls into.



CRISPR Therapeutics AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN3,395 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CRISPR Therapeutics AG  (MEX:CRSP) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


CRISPR Therapeutics AG Revenue Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.